methylphenidate has been researched along with Weight Loss in 14 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
Weight Loss: Decrease in existing BODY WEIGHT.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A retrospective analysis included children with a history of brain tumor and hypothalamic obesity receiving methylphenidate (10-60 mg/day) for hypothalamic obesity." | 7.96 | Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity. ( Bielamowicz, K; Hilsenbeck, S; Horne, VE; Lindsay, H; Nguyen, J; Okcu, F; Sisley, S; Sonabend, R; Wood, AC, 2020) |
| " Obese patients (n = 101) were randomized in a 1:2:2 ratio to either (i) standard nutrition counselling; or (ii) the Department of Veterans Affairs weight loss programme called 'motivate obese veterans everywhere ' (MOVE); or (iii) methylphenidate treatment plus the MOVE programme together." | 5.16 | Role of apathy in the effectiveness of weight management programmes. ( Anzures, P; Demasi, C; Desouza, CV; Haynatzki, G; Padala, PR; Shivaswamy, V, 2012) |
| "A retrospective analysis included children with a history of brain tumor and hypothalamic obesity receiving methylphenidate (10-60 mg/day) for hypothalamic obesity." | 3.96 | Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity. ( Bielamowicz, K; Hilsenbeck, S; Horne, VE; Lindsay, H; Nguyen, J; Okcu, F; Sisley, S; Sonabend, R; Wood, AC, 2020) |
| "A significant dose-response reduction in eating was observed across all genotypes (p < 0." | 2.74 | Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths. ( Epstein, LH; Erbe, R; Gnagy, EM; Leddy, JJ; Mahaney, P; Paluch, RA; Pelham, WE; Salis, RJ; Waxmonsky, JG, 2009) |
| " Headache, anorexia, and insomnia were the most frequently reported treatment-related adverse events." | 2.72 | Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder. ( Bukstein, O; Greenhill, L; Lerner, M; McBurnett, K; McGough, JJ; Stein, M; Wilens, TE, 2006) |
| " Therefore, three-times-a-day dosing should be considered for those children exhibiting ADHD symptoms in the evening." | 2.68 | Effects of late-afternoon methylphenidate administration on behavior and sleep in attention-deficit hyperactivity disorder. ( Abikoff, H; Blader, JC; Foley, CA; Kent, JD; Koplewicz, HS, 1995) |
| " An association between two CES1 SNP markers and the occurrence of sadness as a side effect of short-acting methylphenidate was found." | 1.39 | Methylphenidate side effect profile is influenced by genetic variation in the attention-deficit/hyperactivity disorder-associated CES1 gene. ( Barry, E; Bellgrove, MA; Fitzgerald, M; Gill, M; Hawi, Z; Johnson, KA; Kirley, A; Lambert, D; McNicholas, F, 2013) |
| "Although attention deficit hyperactivity disorder is thought to be present in preschoolers, there are no clear guidelines for dosing stimulant medications in this population." | 1.32 | High-dose methylphenidate treatment of attention deficit hyperactivity disorder in a preschooler. ( Butz, AM; Cozen, MA; Lipkin, PH, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Horne, VE | 1 |
| Bielamowicz, K | 1 |
| Nguyen, J | 1 |
| Hilsenbeck, S | 1 |
| Lindsay, H | 1 |
| Sonabend, R | 1 |
| Wood, AC | 1 |
| Okcu, F | 1 |
| Sisley, S | 1 |
| Bou Khalil, R | 1 |
| Smayra, V | 1 |
| Saliba, Y | 1 |
| Hajal, J | 1 |
| Bakhos, JJ | 1 |
| Souaiby, L | 1 |
| Richa, S | 1 |
| Tamraz, J | 1 |
| Farès, N | 1 |
| McCarthy, S | 1 |
| Neubert, A | 1 |
| Man, KKC | 1 |
| Banaschewski, T | 1 |
| Buitelaar, J | 1 |
| Carucci, S | 1 |
| Coghill, D | 1 |
| Danckaerts, M | 1 |
| Falissard, B | 1 |
| Garas, P | 1 |
| Häge, A | 1 |
| Hollis, C | 1 |
| Inglis, S | 1 |
| Kovshoff, H | 1 |
| Liddle, E | 1 |
| Mechler, K | 1 |
| Nagy, P | 1 |
| Rosenthal, E | 1 |
| Schlack, R | 1 |
| Sonuga-Barke, E | 1 |
| Zuddas, A | 1 |
| Wong, ICK | 1 |
| Johnson, KA | 1 |
| Barry, E | 1 |
| Lambert, D | 1 |
| Fitzgerald, M | 1 |
| McNicholas, F | 1 |
| Kirley, A | 1 |
| Gill, M | 1 |
| Bellgrove, MA | 1 |
| Hawi, Z | 1 |
| Ludvigsson, M | 1 |
| Haenni, A | 1 |
| Torres-Reveron, A | 1 |
| Gray, JD | 1 |
| Melton, JT | 1 |
| Punsoni, M | 1 |
| Tabori, NE | 1 |
| Ward, MJ | 1 |
| Frys, K | 1 |
| Iadecola, C | 1 |
| Milner, TA | 1 |
| Leddy, JJ | 1 |
| Waxmonsky, JG | 1 |
| Salis, RJ | 1 |
| Paluch, RA | 1 |
| Gnagy, EM | 1 |
| Mahaney, P | 1 |
| Erbe, R | 1 |
| Pelham, WE | 1 |
| Epstein, LH | 1 |
| Desouza, CV | 1 |
| Padala, PR | 1 |
| Haynatzki, G | 1 |
| Anzures, P | 1 |
| Demasi, C | 1 |
| Shivaswamy, V | 1 |
| Lipkin, PH | 1 |
| Butz, AM | 1 |
| Cozen, MA | 1 |
| McGough, JJ | 1 |
| McBurnett, K | 1 |
| Bukstein, O | 1 |
| Wilens, TE | 1 |
| Greenhill, L | 1 |
| Lerner, M | 1 |
| Stein, M | 1 |
| Kent, JD | 1 |
| Blader, JC | 1 |
| Koplewicz, HS | 1 |
| Abikoff, H | 1 |
| Foley, CA | 1 |
| Schertz, M | 1 |
| Adesman, AR | 1 |
| Alfieri, NE | 1 |
| Bienkowski, RS | 1 |
| Parran, TV | 1 |
| Jasinski, DR | 1 |
| Aman, MG | 1 |
| Kern, RA | 1 |
| Arnold, LE | 1 |
| McGhee, DE | 1 |
5 trials available for methylphenidate and Weight Loss
| Article | Year |
|---|---|
Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Child; Dopa | 2009 |
Role of apathy in the effectiveness of weight management programmes.
Topics: Apathy; Central Nervous System Stimulants; Directive Counseling; Female; Humans; Male; Methylphenida | 2012 |
Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Anorexia; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulan | 2006 |
Effects of late-afternoon methylphenidate administration on behavior and sleep in attention-deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Child, Preschool; Cross-Over S | 1995 |
Fenfluramine and mental retardation.
Topics: Attention Deficit Disorder with Hyperactivity; Double-Blind Method; Encopresis; Enuresis; Fenflurami | 1991 |
9 other studies available for methylphenidate and Weight Loss
| Article | Year |
|---|---|
Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity.
Topics: Brain Neoplasms; Cancer Survivors; Central Nervous System Stimulants; Child; Child, Preschool; Femal | 2020 |
Mifepristone reduces hypothalamo-pituitary-adrenal axis activation and restores weight loss in rats subjected to dietary restriction and methylphenidate administration.
Topics: Adiponectin; Animals; Brain; Caloric Restriction; Central Nervous System Stimulants; Female; Hormone | 2018 |
Effects of long-term methylphenidate use on growth and blood pressure: results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS).
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Body Height; Body Mass In | 2018 |
Methylphenidate side effect profile is influenced by genetic variation in the attention-deficit/hyperactivity disorder-associated CES1 gene.
Topics: Adolescent; Appetite; Attention Deficit Disorder with Hyperactivity; Carboxylic Ester Hydrolases; Ce | 2013 |
Methylphenidate toxicity after Roux-en-Y gastric bypass.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Diabetes Me | 2016 |
Early postnatal exposure to methylphenidate alters stress reactivity and increases hippocampal ectopic granule cells in adult rats.
Topics: Analysis of Variance; Animals; Animals, Newborn; Attention Deficit Disorder with Hyperactivity; Beha | 2009 |
High-dose methylphenidate treatment of attention deficit hyperactivity disorder in a preschooler.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child Behavior; Ch | 2003 |
Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Body Height; Body Mass Index; Central Ner | 1996 |
Intravenous methylphenidate abuse. Prototype for prescription drug abuse.
Topics: Adult; Baltimore; Female; Humans; Lung Diseases; Male; Methylphenidate; Substance Abuse Treatment Ce | 1991 |